233 related articles for article (PubMed ID: 12886869)
1. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer.
Johnson FM; Kurie JM; Peeples BO; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):17-21. PubMed ID: 12886869
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer.
Briasoulis E; Samantas E; Kalofonos H; Skarlos D; Makatsoris T; Christodoulou C; Fountzilas G; Bamias A; Dimopoulos MA; Kosmidis P; Pavlidis N
Cancer Chemother Pharmacol; 2005 Nov; 56(5):521-8. PubMed ID: 15959778
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.
Noda K; Nishiwaki Y; Kawahara M; Negoro S; Sugiura T; Yokoyama A; Fukuoka M; Mori K; Watanabe K; Tamura T; Yamamoto S; Saijo N;
N Engl J Med; 2002 Jan; 346(2):85-91. PubMed ID: 11784874
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
Hanna N; Bunn PA; Langer C; Einhorn L; Guthrie T; Beck T; Ansari R; Ellis P; Byrne M; Morrison M; Hariharan S; Wang B; Sandler A
J Clin Oncol; 2006 May; 24(13):2038-43. PubMed ID: 16648503
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
[TBL] [Abstract][Full Text] [Related]
8. New state of the art in small-cell lung cancer.
Tamura T
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):8-10. PubMed ID: 11221023
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan and cisplatin with concurrent thoracic radiotherapy in a once-every-three-weeks schedule in patients with limited-disease small-cell lung cancer: a phase I study.
de Jong WK; de Jonge MJ; van der Leest AH; van Meerbeeck JP; Groen HJ
Lung Cancer; 2008 Jul; 61(1):123-8. PubMed ID: 18179842
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan plus cisplatin in small-cell lung cancer.
Sandler A
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 9):39-43. PubMed ID: 12375800
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.
Natale RB
Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):22-6. PubMed ID: 12886870
[TBL] [Abstract][Full Text] [Related]
12. Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Allendorf DJ; Bordoni RE; Grant SC; Saleh MN; Reddy VB; Jerome ML; Dixon PM; Miley DK; Singh KP; Robert F
Cancer Chemother Pharmacol; 2015 Nov; 76(5):949-55. PubMed ID: 26395450
[TBL] [Abstract][Full Text] [Related]
13. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
Masuda N
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of small cell lung cancer].
Negoro S
Gan To Kagaku Ryoho; 2005 Jun; 32(6):777-82. PubMed ID: 15984515
[TBL] [Abstract][Full Text] [Related]
15. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
Ueoka H; Tabata M; Kiura K; Shibayama T; Gemba K; Segawa Y; Chikamori K; Yonei T; Hiraki S; Harada M
Br J Cancer; 1999 Feb; 79(5-6):984-90. PubMed ID: 10070901
[TBL] [Abstract][Full Text] [Related]
16. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer.
Ando M; Kobayashi K; Yoshimura A; Kurimoto F; Seike M; Nara M; Moriyama G; Mizutani H; Hibino S; Gemma A; Okano T; Shibuya M; Kudoh S
Lung Cancer; 2004 Apr; 44(1):121-7. PubMed ID: 15013590
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer.
Schmittel A; Schulze K; Hütter G; Krebs P; Thiel E; Keilholz U
Onkologie; 2004 Jun; 27(3):280-4. PubMed ID: 15249718
[TBL] [Abstract][Full Text] [Related]
18. The emerging world role of irinotecan in lung cancer.
Langer CJ
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):15-21. PubMed ID: 11497227
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI).
Sekine I; Nishiwaki Y; Noda K; Kudoh S; Fukuoka M; Mori K; Negoro S; Yokoyama A; Matsui K; Ohsaki Y; Nakano T; Saijo N;
Ann Oncol; 2003 May; 14(5):709-14. PubMed ID: 12702524
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a phase I study.
Klautke G; Fähndrich S; Semrau S; Büscher C; Virchow C; Fietkau R
Lung Cancer; 2006 Aug; 53(2):183-8. PubMed ID: 16757061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
